Payers

At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.

Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.

Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.

Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.

At ASN Kidney Week 2026, experts said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.

Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.

Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.

The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.

The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.

Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.

NCCN survey finds universal, persistent generic drug shortages; coping tactics stretch teams as looming tariffs threaten more supply disruptions.

The action comes after an advisory panel recommended against approval, saying evidence from the did not support a “clinically meaningful benefit."

Previous research has tied the loosening of permit-to-purchase and concealed carry laws to increased firearm suicide rates.

Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events.

How tebentafusp, a BiTE bispecific T-cell engager, changes metastatic uveal melanoma care—HLA testing, dosing, safety and access tips for clinics.

John Kitchens, MD, explores how GLP-1s, novel drug pipelines, and Medicaid access gaps are shaping the future of DME management.

A target trial emulation found GLP-1 RA initiation was associated with a 21% lower 3-year fragility fracture risk compared with DPP-4 inhibitor therapy.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

Closed-loop social care networks move beyond referrals, proving statewide scale can cut ED use and Medicaid costs while tracking real outcomes.

Anti-VEGF has maxed out in diabetic macular edema (DME), but Ang-2 and Wnt pathway approaches could target disease differently, said John Kitchens, MD.

CMS proposes major Medicare reforms to ACOs, physician pay, and MIPS reporting, aiming to reward outcomes over service volume by 2029.

New data suggest epcoritamab plus R2 may win insurer coverage, delivering major QALY gains at approximately $68,000 and delaying costly progression.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.